Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 4, 2011, Pages 357-362

  Neuner, Elizabeth A ^a   Yeh, Jun Yen ^a   Hall, Gerri S ^a   Sekeres, Jennifer ^a   Endimiani, Andrea ^b,c   Bonomo, Robert A ^b,c   Shrestha, Nabin K ^a   Fraser, Thomas G ^a   Van Duin, David ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Carbapenem resistance; Klebsiella pneumoniae; Mortality; Multidrug resistance

Indexed keywords

AMIKACIN; CARBAPENEM; COLISTIMETHATE; COLISTIN; GENTAMICIN; TIGECYCLINE;

ACUTE DISEASE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE BLOODSTREAM INFECTION; CHRONIC DISEASE; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITAL READMISSION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; MINOCYCLINE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952384690     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.013     Document Type: Article

References (29)

1. Ben-Ami R., Rodriguez-Bano J., Arslan H., Pitout J.D., Quentin C., Calbo E.S., Azap O.K., Arpin C., Pascual A., Livermore D.M., Garau J., Carmeli Y. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 2009, 49:682-690.
2. Borer A., Saidel-Odes L., Riesenberg K., Eskira S., Peled N., Nativ R., Schlaeffer F., Sherf M. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect. Control. Hosp. Epidemiol. 2009, 30:972-976.
3. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 2005, 165:1430-1435.
4. Bratu S., Tolaney P., Karumudi U., Quale J., Mooty M., Nichani S., Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 2005, 56:128-132.
5. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2008, 52:570-573.
6. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 1987, 40:373-383.
7. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., Ramphal R., Wagener M.M., Miyashiro D.K., Yu V.L. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 1991, 115:585-590.
8. Chow J.W., Yu V.L. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int. J. Antimicrob. Agents 1999, 11:7-12.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: nineteenth informational supplement. 2009; CLSI document M100-S19.
10. Cobo J., Morosini M.I., Pintado V., Tato M., Samaranch N., Baquero F., Cantón R. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 2008, 60:319-322.
11. Elemam A., Rahimian J., Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis. 2009, 49:271-274.
12. Endimiani A., Hujer A.M., Perez F., Bethel C.R., Hujer K.M., Kroeger J., Oethinger M., Paterson D.L., Adams M.D., Jacobs M.R., Diekema D.J., Hall G.S., Jenkins S.G., Rice L.B., Tenover F.C., Bonomo R.A. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother. 2009, 63:427-437.
13. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Mavromanolakis E., Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 2010, 35:240-243.
14. Gardiner D., Dukart G., Cooper A., Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin. Infect. Dis. 2010, 50:229-238.
15. Gasink L.B., Edelstein P.H., Lautenbach E., Synnestvedt M., Fishman N.O. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 2009, 30:1180-1185.
16. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 2009, 63:775-780.
17. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 2010, 65:1119-1125.
18. Lee K., Chong Y., Shin H.B., Kim Y.A., Yong D., Yum J.H. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin. Microbiol. Infect. 2001, 7:88-91.
19. Nadkarni A.S., Schliep T., Khan L., Zeana C.B. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am. J. Infect. Control 2009, 37:121-126.
20. Nation R.L., Li J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 2009, 22:535-543.
21. Nordmann P., Cuzon G., Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 2009, 9:228-236.
22. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 2008, 29:1099-1106.
23. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., Husain S., Kwak E.J., Bhat S.V., Paterson D.L. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 2007, 59:128-131.
24. Poulakou G., Kontopidou F.V., Paramythiotou E., Kompoti M., Katsiari M., Mainas E., Nicolaou C., Yphantis D., Antoniadou A., Trikka-Graphakos E., Roussou Z., Clouva P., Maguina N., Kanellakopoulou K., Armaganidis A., Giamarellou H. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J. Infect. 2009, 58:273-284.
25. Schwaber M.J., Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008, 300:2911-2913.
26. Souli M., Galani I., Antoniadou A., Papadomichelakis E., Poulakou G., Panagea T., Vourli S., Zerva L., Armaganidis A., Kanellakopoulou K., Giamarellou H. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 2010, 50:364-373.
27. Tigecycline package insert. Wyeth Pharmaceuticals, Madison, NJ. Available at: Accessed February 24, 2010. http://www.wyeth.com/content/showlabeling.asp?id=491.
28. Urban C., Mariano N., Rahal J.J. In vitro double and triple bactericidal activities of doripenem, polymyxin B and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 2010, 54:2732-2734.
29. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.W., Steward C.D., Alberti S., Bush K., Tenover F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2001, 45:1151-1161.